Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
News and updates for Establishment Labs Holdings Inc. (NASDAQ: ESTA) center on its role as a global medical device company dedicated to women’s health, particularly in breast aesthetics and reconstruction. Company announcements frequently highlight developments in its Motiva breast implant portfolio, minimally invasive platforms, and reconstruction technologies, as well as financial performance and corporate events.
Investors and clinicians following ESTA news can expect regular coverage of quarterly and annual financial results, including revenue trends, margins, and cash position as disclosed in earnings releases and accompanying conference calls. The company also reports on financing arrangements, such as amendments to its credit agreement and access to additional term loan tranches, through Form 8-K filings and press releases.
Product and clinical news is a recurring theme. Establishment Labs issues updates on regulatory milestones, such as FDA submissions and indications for Motiva implants in breast augmentation and reconstruction. It also shares outcomes from clinical studies, including prospective trials of Mia Femtech, and annual Post-Market Surveillance reports summarizing real-world performance data for Motiva implants across global markets.
Conference participation and investor outreach are another focus of ESTA news. The company announces presentations at major healthcare investment conferences, including events hosted by J.P. Morgan and Jefferies, where its leadership discusses strategy, product platforms, and market opportunities. For users tracking the ESTA stock, this news feed provides a consolidated view of financial disclosures, regulatory updates, clinical evidence, and corporate presentations related to Establishment Labs.
Establishment Labs (NASDAQ: ESTA) highlighted publication of a 3-year, 100-patient prospective study of Mia Femtech in Aesthetic Surgery Journal showing very low complication rates and no reports of capsular contracture (Baker III/IV), implant rupture, nipple/breast sensitivity loss, infection, seroma, rippling, hematoma, or BIA-ALCL; 3-year reoperation rate was 1%.
Patient follow-up was 93%, patient satisfaction rose 87% at 3 years, and 90% of surgeons were very satisfied. The company expects the minimally invasive platform to generate at least $30 million in 2026. Mia Femtech and Ergonomix2 Diamond implants are available internationally but not cleared for sale in the United States; Preservé is in limited U.S. release.
Establishment Labs (NASDAQ: ESTA) released its 2025 Post-Market Surveillance (PMS) Report on October 9, 2025, summarizing 15 years of real-world Motiva implant data.
The report aggregates peer-reviewed studies, global registries, warranty and claims data, and regulatory-study results, and reports less than 1% device-related complications leading to reoperations across sources. The company cites >15 years of consistent outcomes, >4 million Motiva devices delivered since 2010, and an expectation of approximately 400,000 additional patients next year. The PMS is published annually and is available on the company website.
Establishment Labs (NASDAQ: ESTA) reported Q2 2025 financial results with revenue of $51.3 million, up 16.3% year-over-year. The company increased its 2025 revenue guidance to $208-212 million, representing 25-28% growth. Q2 highlights include $10.3 million in US Motiva sales and improved gross margin of 68.8%.
The company reported a Q2 operating loss of $14.1 million and adjusted EBITDA loss of $8.5 million. Cash balance stood at $54.6 million with an additional $25 million available under credit line. Management expects to achieve positive EBITDA in 2025 and become cash flow positive in 2026.
Establishment Labs Holdings (NASDAQ: ESTA), a global medical technology company focused on women's health and breast aesthetics, will release its Q2 2025 financial results on August 7, 2025, before market open. The company will host a conference call at 8:30 AM ET to discuss the results.
The company has delivered over 4 million Motiva® devices to surgeons since 2010 and operates in more than 90 countries. Their innovative product portfolio includes Mia Femtech®, Preservé™, GEM®, Motiva Flora® tissue expander, and Zensor™ RFID technology. The company maintains two FDA-compliant manufacturing facilities in Costa Rica and holds over 200 patent applications across 20 patent families.
Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company focused on women's health and breast aesthetics, will release its Q1 2025 financial results on May 7, 2025 after market close. The company will host a conference call at 4:30 pm ET with conference ID 13750827.
The company has delivered over 4 million Motiva® devices to surgeons since 2010 across 90+ countries. Their product portfolio includes:
- Mia Femtech® for breast harmonization
- Preservé™ for breast augmentation
- GEM® for gluteal modeling (in pivotal study)
- Motiva Flora® tissue expander for breast reconstruction
- Zensor™ RFID technology with Zenº™ biosensor
Establishment Labs operates two FDA-compliant manufacturing facilities in Costa Rica under ISO13485:2024 standards, supported by 200+ patent applications and 100+ scientific studies.
Establishment Labs Holdings (NASDAQ: ESTA) has released preliminary Q1 2025 results, expecting revenue of approximately $41.4 million, including $6.2 million from Motiva sales in the United States. The company maintains its 2025 revenue guidance of $205-210 million.
The US launch of Motiva is showing strong momentum, with March orders exceeding 100 per day. The company expects to achieve EBITDA positivity in 2025 and cash flow positivity in 2026, with anticipated tariffs having minimal impact (less than 50-basis points) on gross margins.
The company announced an upcoming investor day on June 12, 2025 in New York City, where leadership will present updates on the US Motiva launch, innovation roadmap, and financial outlook.